<DOC>
	<DOCNO>NCT00091845</DOCNO>
	<brief_summary>Although serious form West Nile Virus ( WNV ) disease , refer neuroinvasive disease , rare , result permanent disability occasionally death . For patient get serious form WNV disease , approve specific treatment option . The purpose study test new drug , AVI-4020 Injection , patient hospitalize recent symptom form WNV disease . In study , determine AVI-4020 treatment safe . This accomplish review result laboratory test clinical sign symptom . Additionally , review patient data sign AVI-4020 provide beneficial effect WNV neuroinvasive disease .</brief_summary>
	<brief_title>An Exploratory Study AVI-4020 Patients With Possible Acute Neuroinvasive West Nile Virus ( WNV ) Disease</brief_title>
	<detailed_description>1 . To evaluate safety intravenously administer ( IV ) AVI-4020 Injection every 12 hour total ten dos course study surveillance . 2 . To evaluate tolerability intravenously administer AVI-4020 Injection every 12 hour total ten dos course study surveillance . 3 . To evaluate effectiveness intravenously administer AVI-4020 Injection 45 mg every 12 hour ten dos , base neurological status study Subject measure combination NIH stroke scale score Glasgow coma scale score . 4 . To evaluate robustness potential effectiveness intravenously administer AVI-4020 Injection every 12 hour ten dos course 35 day active surveillance , base variety criterion , e.g. , clinical , laboratory and/or neurophysiological result .</detailed_description>
	<mesh_term>West Nile Fever</mesh_term>
	<criteria>Subject positive serum CSF ELISA MACIgM test indicate active/recent WNV infection , Subject reside travel geographic area least one follow characteristic within last seven day : 1 . Documented evidence WNV infect mosquito sentinel animal within last 30 day 2 . Documented evidence WNV infect dead animal within last 30 day 3 . Documented human case WNV infection/disease within last two week Subject &gt; 18 &lt; 75 year age . Subject develop febrile disease new neurological finding &lt; 4 day prior current hospitalization . Subject oral temperature &gt; 38 degree Celsius within 48 hour study entry . Subject must one follow acute sign time study entry : 1 . Signs meningitis ( nuchal rigidity ) 2 . Signs encephalitis ( change mental status ) 3 . Evidence brainstem , cranial nerve , cerebellar dysfunction 4 . Limb weakness . Subject must CSF examination within 48 hour study entry showing : 1 . Absence organisms Gram fungal stain 2 . White blood cell count &gt; 4 per mm3 ( correct significant red blood cell contamination ) 3 . Ratio CSF glucose : plasma glucose &gt; 0.40 ; CSF protein &gt; 30 mg/dL Subjects reproductive potential must agree practice adequate birth control method protect partner conception define : 1 . Men reproductive potential eligible participate use acceptable method contraception ( condom spermicide ) . 2 . Women childbearing potential eligible participate surgically sterile ( via hysterectomy bilateral tubal ligation ) least one year postmenopausal , use acceptable method contraception ( oral , topical , injected contraception , IUD , NuvaRingÂ® , double barrier method diaphragm condom spermicide ) . Subject ( family legal guardian ) request Do Not Resuscitate Do Not Intubate order . Subject multisystem organ failure time screen expect survive next 12 month due another cause . Subject history vaccine administration &lt; 30 day prior study entry . Subject possible history traumatic neuritis &lt; 7 day prior study entry ( e.g. , acupuncture , needleadministered drug , automobile accident , and/or blunt trauma ) . Subject female pregnant breastfeeding . ( If Subject postmenopausal surgically sterilize , negative serum pregnancy test require within 72 hour prior administration first dose study drug . ) Subject follow clinically significant abnormal laboratory result : 1 . Serum creatinine great 3.0 mg/dL study Subject require hemodialysis 2 . Liver function test twice upper limit normal 3 . Total bilirubin level twice upper limit normal 4 . PT INR twice upper limit normal Documented presence bacterial nonWNV viral agent CSF Principal Investigator opinion Subject 's medical condition ( ) state mental health would prevent adherence protocol requirement hinder interpretation clinical study result .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>West Nile Fever Myelitis</keyword>
	<keyword>West Nile Fever Encephalitis</keyword>
	<keyword>West Nile Fever Meningitis</keyword>
	<keyword>West Nile Fever Meningoencephalitis</keyword>
</DOC>